ADMETRx, a contract research group that provides in vitro ADME discovery support, will collaborate with Roche to advance the development of its multicriteria decision-making models applied to drug discovery.

ADMETRx chief executive officer and chief scientific officer Phil Burton, Ph.D., said, “Effectively using all the data available in a discovery program to prioritize or advance candidates with the best development potential is a significant challenge in the pharmaceutical industry. The multi-criteria decision-making methods developed by ADMETRx are intended to help Roche scientists to make these critical decisions, ultimately improving the success of candidates at each step in the development process.”